Detected ·
STORM Therapeutics
——
STORM Therapeutics secured $56M Series C financing to advance STC-15, an oral first-in-class inhibitor of METTL3, as they progress their RNA epigenetics platform in oncology and dosed first patient in Phase 2 sarcoma trial.
- Website
- —
- —
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-04-28 00:05:10 UTC
- Signal ID
- f0517d82-067e-42c7-8640-198be27006e8
As the API returns it
{
"id": "f0517d82-067e-42c7-8640-198be27006e8",
"created_at": "2026-04-28T00:05:10.126047Z",
"company_name": "STORM Therapeutics",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*STORM Therapeutics secured $56M Series C financing to advance STC-15, an oral first-in-class inhibitor of METTL3, as they progress their RNA epigenetics platform in oncology and dosed first patient in Phase 2 sarcoma trial.*"
}